Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients (NIS-PUB)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01292915
First received: February 9, 2011
Last updated: May 15, 2014
Last verified: May 2014

February 9, 2011
May 15, 2014
October 2011
January 2013   (final data collection date for primary outcome measure)
Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode) [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01292915 on ClinicalTrials.gov Archive Site
  • Surgery due to re-bleeding [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Mortality due to bleeding [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Rebleeding in high risk peptic ulcer patients [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients
Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients

The main aim of the study is to describes the outcomes of patients with Upper Gastrointestinal Bleed (UGIB) in a real-life setting. Additionally analyse assessed predictors of outcome, including the impact of hemostatic endoscopic and pharmacologic therapies.

MSD

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

NVUGIB patients in 13 hospitals in Hanoi, HCMC, Danang

Re-bleeding in NVUGIB
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1044
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients (>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia...
  • Evidence that an upper GI endoscopy was performed

Exclusion Criteria:

  • GI bleeding not from NVUGIB
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Vietnam
 
NCT01292915
NIS-GVN-DUM-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Dao Van Long, MD,PhD Hanoi Medical University Hospital
AstraZeneca
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP